Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 27, 2011

Japan Approves Novartis’ MS Drug Gilenya and CAPS Treatment Ilaris

  • Japanese regulatory authorities approved Novartis’ once-daily multiple sclerosis (MS) drug Gilenya and also the firm’s IL-1 beta-targeting mAb Ilaris for the treatment of adults and children with the autoinflammatory disorder cryopyrin-associated periodic syndrome (CAPS).

    The Gilenya sanction covers use of the drug for preventing relapse and delaying progression of physical disability in adult MS patients. The only other drug licensed in Japan for preventing relapse of MS patients is interferon beta. Gilenya is already approved in over 50 countries including the U.S. and nations in the EU.

    Clearance of Ilaris in Japan represents the first for a therapy for CAPS. It covers use of the drug for treating all CAPS disease phenotypes including familial cold auto-inflammatory syndrome, Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease. The drug is currently approved in 50 or so countries including the U.S. and those in the EU for the treatment of adults and children with CAPS. The compound is also being evaluated in diseases including juvenile idiopathic arthritis and gouty arthritis as well as for the secondary prevention of cardiovascular events.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »